# Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer

> **NCT04540692** · PHASE3 · RECRUITING · sponsor: **Latin American Cooperative Oncology Group** · enrollment: 444 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Docetaxel or Paclitaxel
- **DRUG:** Cyclophosphamide + Doxorrubicin

## Key facts

- **NCT ID:** NCT04540692
- **Lead sponsor:** Latin American Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-12
- **Primary completion:** 2026-04
- **Final completion:** 2030-08
- **Target enrollment:** 444 (ESTIMATED)
- **Last updated:** 2024-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04540692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04540692, "Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04540692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*